# A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Study · id `cardio:ct-nct01649297` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01649297](<https://clinicaltrials.gov/study/NCT01649297>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01649297

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 983 participants.

## Technical summary

Registry record NCT01649297. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2015-07-23.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 983 participants (enrolled count; ClinicalTrials.gov record NCT01649297, source copy `cardio:ctgov-nct01649297-2015-07-23`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01649297, source copy `cardio:ctgov-nct01649297-2015-07-23`, retrieved 2026-10-26)
- Primary completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01649297, source copy `cardio:ctgov-nct01649297-2015-07-23`, retrieved 2026-10-26)
- Completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01649297, source copy `cardio:ctgov-nct01649297-2015-07-23`, retrieved 2026-10-26)
- Results first posted: 2015-07-23 (ClinicalTrials.gov record NCT01649297, source copy `cardio:ctgov-nct01649297-2015-07-23`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Estonia; France; Georgia; Germany; Guatemala; Italy; Latvia; Lithuania; Mexico; New Zealand; Poland; Russia; South Africa; Spain; Ukraine (ClinicalTrials.gov record NCT01649297, source copy `cardio:ctgov-nct01649297-2015-07-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01649297-2015-07-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): empagliflozin (low dose qd)
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Empagliflozin (high dose qd)
- Intervention (Drug): empagliflozin (high dose bid)
- Intervention (Drug): Placebo
- Intervention (Drug): empagliflozin (low dose bid)
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 3854a1f91d1c99a2a762443c5e92357e245c07f4b037d1c3edd324385641071b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
